JPMorgan Chase & Co. Trims Stock Holdings in Alto Neuroscience, Inc. (NYSE:ANRO)

JPMorgan Chase & Co. lessened its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 57.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,241 shares of the company’s stock after selling 14,074 shares during the quarter. JPMorgan Chase & Co.’s holdings in Alto Neuroscience were worth $43,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Jane Street Group LLC acquired a new stake in Alto Neuroscience during the third quarter valued at $124,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Alto Neuroscience in the 4th quarter valued at approximately $74,000. Rhumbline Advisers raised its holdings in shares of Alto Neuroscience by 24.4% in the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after buying an additional 5,008 shares during the period. Barclays PLC increased its stake in Alto Neuroscience by 872.7% during the 3rd quarter. Barclays PLC now owns 29,599 shares of the company’s stock worth $339,000 after buying an additional 26,556 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Alto Neuroscience by 15.0% in the 4th quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company’s stock valued at $221,000 after buying an additional 6,812 shares during the period.

Analyst Upgrades and Downgrades

ANRO has been the subject of several research reports. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research report on Friday, March 21st. HC Wainwright initiated coverage on shares of Alto Neuroscience in a report on Monday, April 7th. They issued a “buy” rating and a $10.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $15.40.

Alto Neuroscience Stock Down 0.9 %

Shares of ANRO stock opened at $2.17 on Thursday. Alto Neuroscience, Inc. has a 1 year low of $1.60 and a 1 year high of $17.55. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The business’s fifty day moving average is $2.52 and its 200-day moving average is $3.66. The stock has a market cap of $58.75 million, a PE ratio of -0.85 and a beta of 1.87.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09. Equities analysts expect that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.